FDA Grants Fast Track Designation to Abelacimab

The FDA granted Fast Track status to Anthos Therapeutics’ investigational monoclonal antibody, abelacimab, for treatment of patients with cancer-associated blood clots.

Currently available anticoagulants to treat cancer-associated thrombosis are limited options because of an increased risk of bleeding.

Abelacimab, which can be administered intravenously, inhibits the Factor XI enzyme that causes blood coagulation, with less risk of bleeding.

The FDA’s Fast Track designation gives drug sponsors expedited reviews for their treatments for serious medical conditions that address unmet medical needs.